Non-Small-Cell Lung Cancer with HER2 Exon 20 Mutation Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment

JOURNAL OF THORACIC ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. GlaxoSmithKline
2. National Center for Research Resources, a component of the NIH Roadmap for Medical Research [RR024148]